Lipoyl-Homotaurine Derivative (ADM_12) Reverts Oxaliplatin-Induced Neuropathy and Reduces Cancer Cells Malignancy by Inhibiting Carbonic Anhydrase IX (CAIX) by Fragai, Marco et al.
Lipoyl-Homotaurine Derivative (ADM_12) Reverts Oxaliplatin-
Induced Neuropathy and Reduces Cancer Cells Malignancy by
Inhibiting Carbonic Anhydrase IX (CAIX)
Marco Fragai,†,‡ Giuseppina Comito,§ Lorenzo Di Cesare Mannelli,∥ Roberta Gualdani,†
Vito Calderone,†,‡ Alexandra Louka,‡ Barbara Richichi,† Oscar Francesconi,† Andrea Angeli,∥
Alessio Nocentini,∥ Paola Gratteri,∥ Paola Chiarugi,§ Carla Ghelardini, Francesco Tadini-Buoninsegni,†
Claudiu T. Supuran,*,∥ and Cristina Nativi*,†,⊥
†Department of Chemistry, University of Florence, via della Lastruccia 3-13, 50019 Sesto Fiorentino, Italy
‡CERM, University of Florence, via L. Sacconi 6, 50019 Sesto Fiorentino, Italy
§Department of Experimental and Clinical Biomedical Sciences, University of Florence, V.le Morgagni 50, 50134 Firenze, Italy
∥Department NEUROFARBA, University of Florence, V.le Pieraccini 6, 50134 Firenze, Italy
⊥FioGen, via L. Sacconi 6, 50019 Sesto Fiorentino, Italy
*S Supporting Information
ABSTRACT: Oxaliplatin (OXA) is a valuable and largely used cancer drug
which induces a serious and intractable neuropathy. The lipoyl-
homotaurine derivative (ADM_12) reverts in vivo OXA-induced neuro-
pathy, and it is an effective antagonist of the nociceptive sensor channel
TRPA1. Unprecedentedly, this safe analgesic showed a synergy with OXA
in vitro and proved to inhibit CA IX, a relevant therapeutic target, clearly
interfering with pancreatic cancer cells’ aggressiveness.
■ INTRODUCTION
The number of cancer patients is increasing worldwide, and a
large majority of them receive antitumoral chemotherapy. The
development of new and effective anticancer drugs has
extended the survival of tumor-bearing hosts, conceivably
raising the proportion of patients having experienced chemo-
therapy-induced neuropathy (CIN).1 CIN is considered one of
the most disabling and invalidating diseases affecting cancer
patients: CIN induces or worsens depression, insomnia, and
distress, greatly affecting the quality of life and often becoming
the treatment-limiting issue in cancer therapy.2,3 Therapeuti-
cally, CIN is still considered an intractable problem. As a matter
of fact, no pharmacological treatments have demonstrated
efficacy in the prevention or therapy of CIN. Mixtures of
opioids and nonopioids, including vitamins and mineral salts,
are generally administrated with scarce or no evidence of
efficacy, confirming CIN as the major concern for both cancer
patients and oncologists.4 Manifestations and causes of CIN
can vary substantially from drug to drug. A distinct, and
probably one of the most difficult to treat, is the neuropathy
induced by oxaliplatin (OXA). Mechanical and cold allodynic
sensation in hands and feet are the painful effects produced
which, surprisingly, may worsen after OXA administration has
finished.2 Thus, the availability of safe and effective analgesic
drugs for the treatment of chronic CIN is a task of primary
importance as well as an urgent need. Acute and chronic
peripheral neuropathies associated with the use of OXA have
extensively been reported5 and related to the remodeling and
alteration in the expression of transient receptors potential
(TRP) Ca2+ channels. In particular, potential thermosensitive
transient receptors vanilloid 1 (TRPV1) and ankyrin 1
(TRPA1) are upregulated and hypersensitized, mediating
OXA-evoked cold and mechanical allodynia.6,7 We recently
reported about the TRPA1 antagonist 1 (ADM_09) (Figure
1),8 which effectively reverts neuropathic pain evoked by OXA
without eliciting the negative side-effects generally observed in
neuropathic pain treatment. Preserving the α-lipoic portion,
which characterizes 1, we have also reported a second lipoic-
containing TRPA1 antagonist, namely 2 (ADM_12) (Figure
1),9 successfully assayed to treat in vivo another orphan pain,
that is, the orofacial pain.9
With respect to 1, 2 presents the lipoic acid portion linked to
an homotaurine and is characterized by a terminal sulfonic acid
residue.9 In a recent paper describing the inhibitory activity of a
bromophenol sulfonic acid vs human (h) carbonic anhydrases
(hCAs, EC 4.2.1.1) implicated in cancer progression,10 some of
us proved the involvement of the sulfonic acid residue in the
binding to the CA IX active site by anchoring to the zinc-
coordinated water molecule. Keeping this in mind and
capitalizing on data we previously reported for 2, we reasoned
that 2 might be an excellent candidate for both the treatment of
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neuropathic pain induced by OXA and as a new inhibitor of
CAs. Hence, we report herein on the investigation of 2 and the
corresponding homologues 3 and 4 (Figure 1) in (a) the
treatment of OXA-induced neuropathy (OXAIN), (b) binding
tests vs CA IX and CA XII, as well as (c) in CA IX-mediated
cancer cells motility tests. Unprecedentedly, our data showed
the double role of 2 as an analgesic but also as a modulator in
cancer cells’ invasiveness.
■ RESULTS
Synthesis. Following the synthetic strategy reported for 2,9
its homologous 3 and 4 were obtained in two steps by reacting
the commercially available (±) α-lipoic acid with N-
hydroxysuccinimide in tetrahydrofuran (THF) as solvent and
in the presence of dicyclohexylcarbodiimide (DCC) to give the
activated lipoic derivative 5 (Scheme 1). The unreacted DCC
and the dicyclohexyl urea formed during the reaction were
removed by crystallization, and pure 5 was treated with taurine
6 or with the amino sulfonic acid 7 in H2O/DMF to afford,
after purification, 3 (60%) or 4 (80%), respectively. As reported
for 3 and 4 (see Scheme 1), the lipoic-containing alcohol 9,
used as control (see below), was obtained by reacting 5 with
the amino alcohol 8 (Supporting Information). After
purification, 9 was isolated as a yellow waxy solid in 60% yield.
Antioxidative Properties. As widely reported,11,12 acute
and chronic neurotoxicities associated with the use of OXA are
Figure 1. Structures of 1, 2, 3, 4, 10, and acetazolamide (AAZ).
Scheme 1. Synthesis of Lipoic-Containing Derivatives 3, 4, and 9
Figure 2. (A) SOD-inhibitable O2
•− levels in astrocyte cell lines. Astrocytes (5 × 105 cells/well, two control wells and two wells pretreated with 2, 3,
or 4) were exposed to 100 μM OXA for 4 h. The effect of 100 μM 2 coincubation on SOD-inhibitable superoxide anion O2
•− on levels are depicted.
The nonspecific absorbance measured in the presence of SOD was subtracted from the total value. Values are expressed as mean ± SEM of three
experiments. **P < 0.01 vs control and ∧∧P < 0.01 vs OXA treatment. (B) OXA-induced neuropathic pain: antihypersensitive effect of 2 in
comparison to 3 and 4. Rats were daily treated ip with 2.4 mg kg−1 OXA (in 0.5% glucose solution). The response to a noxious mechanical stimulus
was evaluated on day 21 by the paw-pressure test. Vehicle (1% CMC) or 30 mg kg−1 2, 3, or 4 were administered po, and measurements were
performed over time. Each value represents the mean ± SEM of 12 rats per group, performed in two different experimental sets. *∧P < 0.01 vs
vehicle + vehicle; ∧∧P < 0.01 vs OXA + vehicle.
Journal of Medicinal Chemistry Article
DOI: 10.1021/acs.jmedchem.7b01237
J. Med. Chem. 2017, 60, 9003−9011
9004
related to the oxidative stress caused by this cancer drug.
Therefore, the antioxidant profiles of 2, 3, and 4 were
evaluated. We measured the oxidation in vitro of nitro blue
tetrazolium (NBT) after 30 min in the absence and in the
presence of an increasing concentration of 2 (Table S2,
Supporting Information). The superoxide anion (O2
•−)
generated by the hypoxanthine−xanthine oxidase system
increased the oxidized NBT level from 100 (basal) to about
4000 a.u. In the presence of 2 in the reaction mixture, the
oxidation of NBT was inhibited in a concentration-dependent
manner, taking effect starting from 10 μM, the highest
concentration (1000 μM) allowed to obtain a complete
prevention of oxidation. Similar results were observed testing
3 and 4 but, differently from 2, they were not able to fully
prevent the oxidation (Supporting Information). The anti-
oxidative properties were also tested in a cell culture of primary
rat cortical astrocytes, a cell type strongly involved in OXA-
dependent neuropathy.13,14 A 4 h long cell treatment with 100
μM OXA induced a significant, SOD-inhibitable, superoxide
anion increase as evaluated by the cytochrome C assay (Figure
2A). The coincubation with 100 μM 2 or 3 or 4 inhibited the
O2
•− formation by about 75% in comparison to the untreated
culture.
Antihyperalgesic Properties. To evaluate the pain-
relieving property of the tested compounds, a painful
neuropathic condition was reproduced in rats with a repeated
treatment with OXA (2.4 mg kg−1, ip, daily). On day 21, the
pain threshold was measured by the paw pressure test by
applying a noxious mechanical stimulus. Oxaliplatin-treated
animals showed (Figure 2B) a decreased threshold reported as
a reduced weight tolerated on the paw (44.7 ± 2.3 g in
comparison to 70.6 ± 2.5 g of control animals). Compound 2,
acutely administered po (30 mg kg−1), counteracted the OXA-
induced hypersensitivity, taking effect 15 min after treatment. A
complete reversion of pain lasted up to 75 min. A similar profile
was observed for compounds 3 and 4 (Figure 2B) even though
a complete reversion of the noxious effect is observed only with
2.
Synergistic Effect of OXA and 2. The soundness data
obtained with 2 in reverting OXAIN in vivo, suggested to
investigate a possible synergistic effect of 2 and OXA. The
activity profile of 2 against tumor cells was thus evaluated in
human colon cancer cell lines HT-29. The incubation with
increasing concentrations of 2 (1−300 μM) for 24 h induced a
progressive decreasing of cell viability as evaluated by MTT
test, reaching 20% of mortality (Table S3, Supporting
Information). Moreover, 2 was also analyzed in the presence
of the neurotoxic anticancer drug OXA. As shown in Table S4,
Supporting Information, OXA in HT-29 cells is active at 30,
100, and 300 μM (24 h). In the presence of 2 (100 μM), OXA
activity was not decreased; on the contrary, 2 increased OXA
potency, decreasing cell viability starting out at 1 μM, reaching
significant differences at 100 and 300 μM (Table 1). The
analysis of synergism performed by the Chou−Talalay method
revealed a combination index (CI) 0.5 considered as
“synergism”.
Inhibition of TRPA1 Activated with OXA. As reported,9
2 can inhibit TRPA1 methanol- and AITC-evoked current with
a low micromolar constant. Thus, using the patch clamp
technique, we investigated the effect of 2 on TRPA1 evoked
current by OXA. After perfusion of OXA 50 μM, we observed
the activation of TRPA1 channel, which is rapidly and
completely reverted in the presence of 2, 30 μM. The
corresponding time courses (Figure 3A) and IV curves (Figure
S2, Supporting Information) are reported (see Table S1 and
Figure S1, Supporting Information, for details about com-
pounds 3 and 4).
Compound 2 Inhibits Carbonic Anhydrases IX and XII.
Carbonic anhydrases (CAs, EC 4.2.1.1) are zinc metallo-
enzymes that catalyze the hydration of carbonic dioxide,
producing bicarbonate and protons.15,16 CA IX is a trans-
membrane enzyme upregulated in many cancer types and
playing an important role in the acidification of the outer
microenvironment under hypoxia, a hallmark of many
tumors.17 The involvement of CA IX to acidification of the
tumor environment has been correlated with the acquisition of
metastatic phenotypes and is related to a decrease in the
success of anticancer drugs.18 Recently, some of us reported on
the nanomolar hCA IX and hCA XII inhibitor 10 (see Figure
1), presenting a sulfonic acid residue involved in the binding to
the CA IX active site by anchoring to the zinc-coordinated
water molecule.10 Of note, currently a sulfonamide CA IX
inhibitor completed phase I clinical trials for the treatment of
advanced stage solid tumors and is scheduled for phase II
trials.19 Keeping in mind the specific CA inhibition mechanism
of 10, we investigated 2 as a possible ligand for CA IX and CA
XII. In fact, even though the properties of 2, 3, and 4 as TRPA1
inhibitors or to revert OXAIPN are rather similar, overall, the
pharmacological profile of 2 is the most interesting. For this
reason, all the following tests have been performed on 2
selected as a lead molecule. We investigated the CA inhibitory
activity of 2 by applying the stopped flow carbon dioxide
hydrase assay (Supporting Information) in comparison to
acetazolamide (AAZ, see Figure 1) as standard CA inhibitor
against the tumor-associated isoforms hCA IX and XII (Table
Table 1. Viability Cell Test (MTT) Run 24 h after the Treatment with OXA and 2a
OXA 1 μM OXA 10 μM OXA 30 μM OXA 100 μM OXA 300 μM
control 100 ± 2.2
2 (100 μM) 81.3 ± 3.1* 74.6 ± 3.2** 78.6 ± 0.8** 71.4 ± 1.1*** 67.4 ± 3.6***∧̂ 48.1 ± 2.6***∧∧∧
aThe % of viable cells with respect to the control is reported. **p < 0.01 and ***p < 0.001 vs control; ∧p < 0.05 and ∧∧∧p < 0.01 vs 2 alone.
Figure 3. (A) Time course obtained from voltage ramps measured at
+50 mV (black circles) and −50 mV (gray circles). OXA (50 μM) and
2 (30 μM) were applied at the time indicated. CHO cells were
transfected with wild-type TRPA1 channel. (B) Summarized data of
TRPA1 whole-cell currents evoked by OXA (50 μM) and OXA + 2
(30 μM). Each column represents mean ± SEM of n = 5 cells. *** p <
0.0001 (unpaired Student’s t test).
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2; see Table S5, Supporting Information, for inhibition data vs
other hCAs and Figure S3, Supporting Information, for dose
response curves). From the data shown in Table 2, 2 clearly
arose as a good hCA IX and hCA XII inhibitor, with Ki ranging
in high nanomolar range (respectively 653.7 and 727.5 nM).
Such results ascribed to 2 are lower in efficacy than the
clinically used AAZ but improved compared to derivative 10.
Anyhow, it should be stressed that the sulfonate derivative 10
originates from the CA-mediated hydrolysis of the correspond-
ing sulfocoumarin necessary to generate the active species from
the original prodrug.10 Conversely, such activation was not
necessary in the case of 2, which can directly bind the active site
pocket.
Molecular Modeling. To fully explore the binding
interaction of the sulfonate derivative 2 within CA active site,
we undertook docking studies by taking into consideration the
tumor-associated isoform hCA IX. In fact, all the attempts to
co-crystallize 2 with CA failed, and at present, only one X-ray
structure of a sulfonate compound within CA is available in
Protein Data Bank, that is, the adduct of derivative 10 with a
modified hCA II (PDB 4BCW).10 This structure, also referred
as hCA II/IX mimic, concerns an engineered protein in which
two amino acid mutations are present in the hCA II active site,
namely A65S and N67Q, serine and glutamine being the
corresponding amino acids found in hCA IX. The sulfonate
group of 10, which as previously mentioned comes from the
CA-mediated hydrolysis of the corresponding sulfocoumarin,10
was found to anchor to the Zn-coordinated water molecule,
differently from compounds containing the sulfonamide moiety
that instead directly coordinates to the Zn ion.20 Considering
that 2 was assayed in vitro against hCA IX (Ki = 653.7 nM), the
target used in such experiments was prepared by superposing
3IAI (hCA IX) and 4BCW (hCA II/IX mimic) through the Zn
ion and the backbone of H94, H96, and H119 residues, then
joining together only the enzyme 3D coordinates of 3IAI and
the catalytic Zn coordinated OH/H2O group of 4BCW. We
report herein only the results obtained for the isomer R, as the
stereocenter is located at the outer rim of the aliphatic tail of
the molecule and barely affects the poses arising from the
docking studies, thus the highlighted binding mode. Taking as
the driving principle in the selection of the docking solutions
the position of the sulfonate group in the X-ray solved
structure, three rather iso-energetic poses were selected, all
characterized by low values of the scoring function (Figures 4
and 5).
In the three different poses, the sulfonate group was always
found to be involved in a wide network of H-bonds (Figure
4A). In particular, two oxygen atoms of the sulfonate moiety
accepted a H-bond from the Zn-bound water molecule, which
in turn donates an additional one to OG1 oxygen of T199 side
chain. Furthermore, one of these sulfonate O atoms established
a H-bond with the backbone NH of T199, whereas the other
one might be considered as “half-coordinated” to the Zn ion.
The three 2 poses are differentiated by the position of the lipoic
tail within the binding site cavity (Figure 4B), and each is
characterized by hydrophobic contacts involving the propylenic
linker and the lipoic moiety which respectively interact with
L198, P201, and P202 (Figure 5A), V121, L91, V131, and Q92
(Figure 5B), and V121, W5, H64, and N62 (Figure 5C).
Moreover, the amidic carbonyl of the conformers in Figure
5B,C is at H bond distance with Q92.
Compound 2 Reduces CA IX-Mediated Acidosis.
Recently, to analyze the role of CA IX in cancer cells’ motility,
we investigated the extracellular pH in normoxia in extracted
human prostate fibroblasts (HPFs) from healthy individuals
affected by prostate hyperplasia, cancer-associated fibroblasts
(CAFs), and in prostate cancer (PCa) cells after the treatment
with conditioned medium (CM) from HPFs or CAFs.21 The
contact of CAFs with PCa cells gives rise to an increase in
extracellular acidity ascribed to CA IX and suggesting that the
conditioning loop among stromal and cancer cells involved in
cancer cells malignancy and aggressiveness also takes into
account acidification of the tumor microenvironment. In Figure
6, we report on the effect of 2 on alkalinization of extracellular
pH in HPFs and CAFs. Fibroblasts were grown to
subconfluence and serum starved for 48 h in the presence of
2 (100 μM); at the end of incubation, the pH of culture
medium was immediately measured by a pH meter. We
observed that the administration of 2 unambiguously reduces
extracellular acidification, confirming a key role of CA IX in this
phenomenon.
Compound 2 Positively Interferes in the Epithelial−
Mesenchymal Transition (EMT) and Invasiveness in PCa
Cells. A specific role is played by CA IX in the regulation of
EMT of cancer cells, a key epigenetic program associated with
increased motility, survival, and stemness.21 In particular, we
demonstrated that PCa cells undergo EMT in response to their
contact with stromal fibroblasts expressing CA IX.21 Here, we
report on the effect of 2 on CAF-mediated EMT. PCa cells
were treated for 72 h with conditioned medium (CM) obtained
from HPFs and CAFs in the presence or not of 2 (100 μM).
Table 2. Inhibition Data of Human CA Isoforms hCA IX and
XII with 2, Compound 10, and the Standard Sulfonamide








aMean from three different assays, by a stopped flow technique (errors
were in the range of ±5−10% of the reported values). bReference
Supporting Information, Figure S7. Inhibitor concentration ranged
from 10−8 to 10−5 M (see also Supporting Information, Figure S3)
Figure 4. (A) Diagram of the H-bond network the sulfonate moiety is
involved in within the active site cavity. (B) Superimposition of the
three orientations found for 2 within hCA IX active site.
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We observed that the use of the compound is active in
impairing EMT in cancer cells due to CAFs contact (Figure
7A), preventing the elongation of the cells, as well as the
expression of known EMT markers, as E-cadherin decrease and
upregulation of Vimentin (Figure 7B).
In keeping rounded morphological features, 2 clearly affects
invasiveness of cancer cells. We finally treated cells with CM
from fibroblasts in the presence or not of 2 and assayed for
their ability to invade through reconstituted matrigel barrier.
Our data revealed that the ability of CAFs to elicit a pro-
invasive behavior of cancer cells is severely impaired during the
administration of 2 (Figure 8).
Compound 2 is a MMPs Inhibitor. As above-discussed,
stromal CA IX leads to extracellular acidification. Because the
sensitivity of MMPs to acidity is acknowledged and the key role
played by CA IX in MMP-2 and MMP-9’s secretion by CAFs is
documented,21 we reasoned that, given the similar active-site
topology of MMPs and CAs, it would be worthy to investigate
the binding properties of 2 vs MMPs. The intrinsic high
similarity of human MMPs’ active site, including MMP-2,
MMP-9, and MMP-12, is well documented,22,23 therefore, the
catalytic domain of human MMP-12 has been used as a
representative model of the whole protein family to analyze the
Figure 5. Simulated binding modes of compound 2 within hCA IX active site (PDB 3IAI): three diverse orientations are shown in panels A−C. The
hydrogen bonds are shown as yellow dashed lines.
Figure 6. Effect of 2 on alkalinization of extracellular pH in HPF and
CAF. Cells were serum starved and treated with 100 μM of 2 for 48h.
*p < 0.05 vs CAF.
Figure 7. (A) HPF and CAF were treated with 100 μM of 2 for 48 h and CM were harvested. PCa cells were then treated with serum free medium
or different CM for 72 h and then were photographed (B) Left: evaluation of E-cadherin and Vimentin in the same experimental setting described in
A. (B) Right: actin immunoblot was used for normalization. Cadherin expression was shown in bar graph, a.u. = arbitrary units.
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structural basis for the interaction of MMPs with the
investigated scaffold. To determine the binding affinity of 2
for the catalytic domain of MMP-12, we analyzed the alteration
of the chemical shifts observed in 2D 1H−15N HSQC spectra of
the protein upon the titration with the lipoic acid derivative.
Several residues forming the S1′ cavity and two zinc binding
histidines experience a sizable chemical shift variation at
submillimolar concentration of the ligand (see Figure 9). The
fit of the experimental data provided a dissociation constant of
875 ± 78 μM.24
The uncommon structure of 2 as MMP inhibitor deserved a
more accurate investigation. Thus, a detailed structural
characterization of the complex MMP-12-2 by X-ray diffraction
was carried out to investigate the binding mode and the
involvement of the catalytic zinc in ligand binding. To confirm
the structural data obtained, compound 9 (see Scheme 1) was
synthesized and X-ray diffraction of the complex MMP-12−9
performed. Compound 9 preserves the lipoic portion but
presents a propyl alcohol replacing the propyl sulfonate residue
of 2 (see Scheme 1).
Compound 2 and 9 Are Non-Zinc Binding Ligands of
MMP-12. In both structures, AHA (hydroxamic acid, see
Supporting Information) is not displaced by 2 or 9 and shows
its typical binding to the catalytic zinc at full occupancy:25 it
chelates zinc with the two oxygens and establishes hydrogen
bond interactions with the carbonyl amide oxygen of A182 and
with a carboxylate oxygen of the catalytic E219. As
consequence, the two lipoic-containing ligands do not interact
directly with the catalytic zinc ion. As a matter of fact, the
sulfonate residue (2) points outside the MMP-12’s site and is
placed at the very entrance of the substrate groove, in addition,
one of the sulfonate oxygens is at 3.1 Å distant from the NH
moiety of Y240. A second sulfonate oxygen is 2.7 Å far from the
amidic carbonyl oxygen of G179. (Figure 10).
Likewise, the hydroxyl group of ligand 9 is located in the
proximity of the groove entrance and it does not interact with
any protein residue (Figure S6, Supporting Information). Both
ligands bend similarly upon binding to the protein in such a
way that the heterocyclic portion is accommodated into the S1′
pocket (Figure 11), while the chain occupies the groove
normally occupied by the substrate before being hydrolyzed.
The electron density of the lipoic-containing ligands appears of
good quality in both cases, supporting their full occupancy; in
detail, it shows that the heterocyclic ring of both 2 and 7,
containing a disulfide bridge, remains closed, witnessing that
the S−S function is not reduced. In the case of the sulfonate
Figure 8. Left: invasion analysis of Pca cells after treatment for 24 h with different CM obtained from HPF or CAF (control or in the presence of 2,
100 μM). Right: bar graph represents the mean of invading cells. *** <0.001 vs untreated CAF.
Figure 9. 1H−15N HSQC spectrum of the catalytic domain of MMP-
12 in the absence (red) and presence of 2 (3.3 mM) (blue), with the
surface model of MMP-12 showing in red the residues experiencing
the largest chemical shifts variation.
Figure 10. AHA and 2 placed into MMP-12 site. Hydrogen binding
interactions are indicated as yellow dotted lines.
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ligand, 2, the two sulfur atoms of the ring into the S1′ pocket
are placed at 3.6 Å from the carbonyl amide oxygens of V235
and F237. In the case of the OH ligand (compound 9), the ring
is slightly tilted so that the two sulfur atoms are at 3.6 Å from
the carbonyl oxygens of T239 and K241. Moreover, the
carbonyl amide oxygen present in the middle of the ligands
points toward AHA, whereas the hydroxyl group of 9 and the
sulfonate of 2 protrude outside the molecule toward the solvent
(Figure 11).
■ DISCUSSION AND CONCLUSION
So far, OXA is the cancer drug commonly used to treat
colorectal and resistant prostate cancer. However, the oxidative
stress triggered by OXA induces a neuropathy, which is
considered the neuropathic pain the most difficult to treat. In
this article, we showed the properties of 2 to revert OXAIN in
an experimental animal model, and we proved 2 effective in
reducing cancer cells invasiveness by inhibiting CA IX in vitro.
Compound 2, formed by a lipoic acid residue linked to the
homotaurine, has a remarkable safe profile in terms of cells
viability and cardiotoxicity.9 To exclude a possible effect of the
distance between the cyclic disulfide and the sulfonic acid tail
on the biological properties of 2, the lower homologue 3 and
the higher homologue 4 were synthesized. The lipoic portion of
2 reasonably accounts for the antioxidative properties we
assessed in vitro (NBT test, Table S2, Supporting Information,
and astrocytes cell culture Figure 2). In vivo, 2, administered to
rat previously treated with OXA, completely counteracted the
OXA-induced hypersensitivity (see Figure 2B). The oxidative
stress caused by OXA is also known to trigger the activation of
the TRPA1 channel, evoking a noxious stimulus;7 we confirmed
2 as an efficient inhibitor of TRPA1,9 able to completely revert
the OXA-induced activation of the channel (Figure 3).
Compound 2 and the two homologues, namely 3 and 4,
showed similar antioxidative properties, close effects as TRPA1
inhibitors as well as in in vivo tests. This allows exclusion of any
effect due to the distance between the disulfide bridge and the
sulfonic acid portion.
The functional contribution of CA IX to specific biological
processes critical for cancer progression, including pH
regulation, migration, and invasion, provide the rational for
its use as relevant therapeutic target.18 In 2015, it was published
the first example of CA IX inhibitor characterized by a sulfonate
residue (see compound 10, Figure 1). Considering the
structural features of 2, we investigated its binding affinity vs
CA IX and CA XII, both involved in cancer progression. Tests
of inhibition vs hCA IX and hCA XII clearly showed a high
nanomolar affinity of 2 for both the CAs (Table 1). The
binding interactions of the sulfonate 2 with the CA active site,
explored while running computational studies, allowed us to
properly rationalize the good inhibition constants assessed. We
confirmed these inhibition properties by testing 2 in CA IX-
mediated biochemical processes. We observed that the
administration of 2 reduces extracellular acidification and
clearly impairs EMT in cancer cells (Figure 7), preventing
the expression of ETM markers and reducing invasiveness of
cancer cells (Figure 8). These results were boosted by the
synergist effect observed for 2 and OXA when used to treat
HT-29 cancer cells (Table 1). These preliminary data suggest
that the use of OXA and 2 in combination might allow
decreasing of OXA concentration in therapy, reducing the
painful effects produced. The binding properties of 2 vs MMPs
were also examined. The chemical shifts recorded by 2D
1H−15N HSQC spectra of MMP-12 (model for the MMPs
family, including the acidity sensitive MMP-2 and MMP-9)
upon the titration with 2 provided a high micro molar Kd value.
X-ray diffraction, carried out to investigate the binding mode of
2, showed that it is a non-zinc binding ligand of MMP-12.
Concluding, the simple structure of 2 collects unique biological
properties: (i) it blocks OXA-induced TRPA1 current, (ii)
reverts in vivo OXAIN, (iii) has a synergistic effect with OXA,
(iv) inhibits CA IX and CA XII, two CAs involved in tumor
progression, and (v) impairs EMT and invasiveness in cancer
cells. Even though the inhibition of CAs should be confirmed in
vivo, the unique properties of 2 and the soundness of the data
reported could represent a glimmer in the dark scenario
exposed to cancer patients suffering from the side effects related
to the chronic administration of chemotherapy and from the
intractable neuropathic pain induced by chemotherapy.
■ EXPERIMENTAL SECTION
Materials and Methods. Patch-clamp studies were carried out in
Chinese hamster ovary (CHO) cells transiently expressing TRPA1
channel. For heterologous protein expression, cells were plated in 6-
well cell culture dishes with 2 mL of growth medium, 24 h before
transfection. Cells were transiently transfected using X-tremeGENE 9
transfection reagent (Roche) according to the protocol supplied by the
manufacturer. EGFP fluorescence was used as marker of successful
transfection. Electrophysiology studies were performed 48−72 h after
transfection. Purity (≥95%) of compounds 3, 4, and 9 was determined
by HRMS.
Male Sprague−Dawley (SD) rats (Harlan, Varese, Italy) weighing
approximately 200−250 g at the beginning of the experimental
procedure were used. Pirc (F344/NTac-Apcam1137) rats, originally
obtained from Taconic (Taconic Farms, Inc. USA), were bred in
CESAL (Centro Stabulazione Animali da Laboratorio, University of
Florence, Italy) in accordance with the Commission for Animal
Experimentation of the Italian Ministry of Health. Animals were
housed in CeSAL and used at least 1 week after their arrival.
2-(5-(1,2-Dithiolan-3-yl)pentammidoethanesulfonic Acid (3)
and 4-(5-(1,2-Dithiolan-3-yl)pentamido)butane-1-sulfonic Acid
(4): General Procedure. The activated lipoic acid 5 in DMF/H2O as
solvent was treated at room temperature with the aminosulfonic
derivative 626 or 7 to afford after purification by column
chromatography on silica gel the derivatives 3 (60%) or 4 (80%),
respectively, obtained as sodium salt. Compound 3: Column
chromatography on silica gel (eluent: CH2Cl2/MeOH 4/1; 5/2);
glassy solid. 1H NMR (500 MHz, D2O): δ 3.67−3.62 (m, 1H, CH-3),
3.53−3.50 (t, 3J(H,H) = 6.8 Hz, 2H, CH2-10), 3.22−3.12 (m, 2H, CH2-
1), 3.06−3.02 (t, 3J(H,H) = 6.8 Hz, 2H, CH2-9), 2.46−2.41 (m, 1H,
CH-2′), 2.23−2.20 (m, 2H, CH2-7), 1.95−1.91 (m, 1H, CH-2), 1.73−
1.56 (m, 3H), 1.40−1.36 ppm (m, 3H). 13C NMR (125 MHz, D2O): δ
Figure 11. View of the interaction of 2 (left, PDB 5N5J) and 9 (right,
PDB code 5N5K) with MMP-12. The two ligands and AHA are
represented as green sticks, the protein as transparent surface, and the
catalytic zinc as yellow sphere.
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176.8, 56.5, 49.8, 40.3, 38.1, 35.5, 35.0, 33.7, 27.9, 24.9 ppm. HRMS
calculated for C10H18NO4S3
− [M − H]−: 312.03980. Found:
312.03923. Elemental Anal. (C10H18NNaO4S3) Calculated: C, 35.81;
H, 5.41; N, 4.18. Found: C, 35.78; H, 5.54; N, 4.46. Compound 4:
Column chromatography on silica gel (eluent: CH2Cl2/MeOH 4/1;
5/2); glassy solid. 1H NMR (500 MHz, D2O): δ 3.68−3.63 (m, 1H,
CH-3), 3.20−3.12 (m, 4H, CH2-1, CH2-12), 2.88−2.85 (m, 2H, CH2-
9), 2.46−2.42 (m, 1H, CH-2), 2.21−2.18 (m, 2H, CH2-7), 1.96−1.92
(m, 1H, CH-2′), 1.72−1.67 (m, 3H), 1.59−1.57 (m, 5H), 1.40−1.35
(m, 2H). 13C NMR (125 MHz, D2O): δ 176.8, 56.5, 50.6, 40.3, 38.8,
38.1, 35.6, 33.7, 27.8, 27.4, 25.1, 21.6 ppm. HRMS calculated for
C12H22NO4S3
− [M − H]−: 340.07110. Found: 340.07008. Elemental
Anal. (C12H22NNaO4S3) Calculated: C, 39.65; H, 6.10; N, 3.85.
Found: C, 39.58; H, 6.32; N, 4.05.
5-(1,2-Dithiolan-3-yl)-N-(3-hydroxypropyl)pentanamide (9).
A solution of the amino alcohol 8 (390 mg, 5.19 mmol) in DMF/H2O
was treated at room temperature with solid NaHCO3 (5.19 mmol)
then cooled to 0 °C. A solution of 5 (1.5 g, 4.94 mmol) in DMF was
added and the reaction mixture warmed to room temperature and
stirred overnight. Water (100 mL) was then added to the mixture and
the organic layer extracted with EtOAc (2×). The crude (1.4 g) was
purified by column chromatography on silica gel (eluent MeOH/
DCM-8/1) to afford 9 as waxy solid (770 mg, 60%). Column
chromatography on silica gel (eluent: CH2Cl2 with 8% MeOH); waxy
solid. 1H NMR (500 MHz, CDCl3): δ 6.30 (bs, 1H, NH), 3.64−3.61
(m, 2H, CH2-11), 3.59−3.54 (m, 1H, CH-3), 3.41−3.38 (m, 2H, CH2-
9), 3.27 (bs, 1H, OH), 3.20−3.09 (m, 2H, CH2-1), 2.49−2.43 (m, 1H,
CH-2), 2.24−2.18 (m, 2H, CH2-7), 1.49−1.87 (m, 1H, CH-2′), 1.75−
1.60 (m, 6H), 1.52−1.42 ppm (m, 2H). 13C NMR (125 MHz,
CDCl3): δ 174.1, 59.4, 56.4, 40.3, 38.5, 36.4, 36.4, 34.6, 32.2, 28.9, 25.5
ppm. HRMS cald for C11H22NO2S2
+ [M + H]+ 264.10920, found
264.10903. Elemental Anal. (C11H21NO2S2) Calculated: C, 50.16; H,
8.04; N, 5.32. Found: C, 50.08; H, 8.30; N, 5.02.
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